Cargando…

Detection of ALK protein expression in lung squamous cell carcinomas by immunohistochemistry

BACKGROUND: The echinoderm microtubule-associated protein-like 4 (EML4) gene and the anaplastic lymphoma kinase (ALK) gene rearrangements occur in approximately 5% of lung adenocarcimomas (ACA), leading to ALK overexpression and predicting response to targeted therapy. To the present, few studies ha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Jiandong, Shen, Qin, Shi, Qunli, Yu, Bo, Wang, Xuan, Cheng, Kai, Lu, Guangming, Zhou, Xiaojun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4304180/ https://www.ncbi.nlm.nih.gov/pubmed/25527865 http://dx.doi.org/10.1186/s13046-014-0109-2

Ejemplares similares

ALK‐rearranged squamous cell carcinoma of the lung
por: Meng, Qiyi, et al.
Publicado: (2021)

ALK-rearranged squamous cell carcinoma of the lung
por: Takanashi, Yusuke, et al.
Publicado: (2015)

Combination of conventional immunohistochemistry and qRT-PCR to detect ALK rearrangement
por: Shan, Ling, et al.
Publicado: (2014)

Screening of ROS1 Rearrangements in Lung Adenocarcinoma by Immunohistochemistry and Comparison with ALK Rearrangements
por: Cha, Yoon Jin, et al.
Publicado: (2014)

Detection of EML4-ALK in Lung Adenocarcinoma Using Pleural Effusion with FISH, IHC, and RT-PCR Methods
por: Liu, Leilei, et al.
Publicado: (2015)

Malakoplakia with aberrant ALK expression by immunohistochemistry: a case report
por: Zhang, Xiao-Ying, et al.
Publicado: (2023)

The Use of P63 Immunohistochemistry for the Identification of Squamous Cell Carcinoma of the Lung
por: Conde, Esther, et al.
Publicado: (2010)

Lack of expression of ALK and CD30 in breast carcinoma by immunohistochemistry irrespective of tumor characteristics
por: Nassif, Samer, et al.
Publicado: (2019)

Performance of a RT-PCR Assay in Comparison to FISH and Immunohistochemistry for the Detection of ALK in Non-Small Cell Lung Cancer
por: Hout, David R., et al.
Publicado: (2017)

Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening
por: Lee, Jeeyun, et al.
Publicado: (2015)

p40 Immunohistochemistry Is an Excellent Marker in Primary Lung Squamous Cell Carcinoma
por: Affandi, Khairunisa Ahmad, et al.
Publicado: (2018)

ALK (D5F3) CDx: an immunohistochemistry assay to identify ALK-positive NSCLC patients
por: Uruga, Hironori, et al.
Publicado: (2018)

Concordance Between Tissue ALK Detection by Immunohistochemistry and Plasma ALK Detection by Next-Generation Sequencing in the Randomized Phase 3 ALEX Study in Patients With Treatment-Naive Advanced ALK-Positive NSCLC
por: Noé, Johannes, et al.
Publicado: (2022)

MUC4 immunohistochemistry is useful in distinguishing epithelioid mesothelioma from adenocarcinoma and squamous cell carcinoma of the lung
por: Mawas, Amany Sayed, et al.
Publicado: (2018)

Two Cases of ALK-Altered Cancers of Unknown Primary Diagnosed by Immunohistochemistry
por: Kato, Yoriko, et al.
Publicado: (2022)

Human Papillomavirus Detection in Oropharyngeal Squamous Cell Carcinoma Using p16 Immunohistochemistry
por: Sabu, Annetmary, et al.
Publicado: (2019)

The Utility of Immunohistochemistry in Differentiating Metastatic Primary Squamous Cell Carcinoma of the Thyroid from a Primary Lung Squamous Cell Carcinoma
por: Kao, Nern Hoong, et al.
Publicado: (2019)

Targeted Resequencing Reveals ALK Fusions in Non-Small Cell Lung Carcinomas Detected by FISH, Immunohistochemistry, and Real-Time RT-PCR: A Comparison of Four Methods
por: Tuononen, Katja, et al.
Publicado: (2013)

Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations
por: Lewis, Whitney E., et al.
Publicado: (2021)

Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study)
por: Takeuchi, K., et al.
Publicado: (2016)

Fluorescence In Situ Hybridization and Immunohistochemistry as Diagnostic Methods for ALK Positive Non-Small Cell Lung Cancer Patients
por: Martinez, Pablo, et al.
Publicado: (2013)

Accurate Identification of ALK Positive Lung Carcinoma Patients: Novel FDA-Cleared Automated Fluorescence In Situ Hybridization Scanning System and Ultrasensitive Immunohistochemistry
por: Conde, Esther, et al.
Publicado: (2014)

Multiple recurrent squamous cell carcinomas and utility of anticytokeratin immunohistochemistry
por: Pelster, Michael W., et al.
Publicado: (2016)

Brigatinib treated ALK positive lung squamous cell carcinoma after failed chemotherapy: A case report
por: Li, Shuluan, et al.
Publicado: (2021)

Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative
por: Ma, Di, et al.
Publicado: (2016)

Comparison of Next-Generation Sequencing and Ventana Immunohistochemistry in Detecting ALK Rearrangements and Predicting the Efficacy of First-Line Crizotinib in Patients with Advanced Non-Small Cell Lung Cancer
por: Zeng, Liang, et al.
Publicado: (2020)

ALK-Positive Squamous Cell Carcinoma Dramatically Responded to Alectinib
por: Sagawa, Ray, et al.
Publicado: (2018)

Efficacy and Drug Resistance Analysis of ALK Inhibitors in Combination with Stereotactic Body Radiation Therapy for Treating Lung Squamous Carcinoma Patient Harboring EML4-ALK Rearrangement
por: Liang, Long, et al.
Publicado: (2021)

Cutaneous squamous cell carcinoma with subtle perineural invasion detected with cytokeratin and epithelial membrane antigen immunohistochemistry
por: Lee, Alison K., et al.
Publicado: (2018)

Role of immunohistochemistry in the diagnosis and staging of cutaneous squamous-cell carcinomas (Review)
por: Bălășescu, Elena, et al.
Publicado: (2022)

A rare double ALK fusion variant EML4-ALK and CDK15-ALK in lung adenocarcinoma and response to crizotinib: A case report
por: Guo, Jun, et al.
Publicado: (2020)

ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature
por: Mamesaya, Nobuaki, et al.
Publicado: (2017)

Status quo of ALK testing in lung cancer: results of an EQA scheme based on in-situ hybridization, immunohistochemistry, and RNA/DNA sequencing
por: Jurmeister, Philipp, et al.
Publicado: (2021)

ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma
por: Dacic, Sanja, et al.
Publicado: (2016)

Acquired ALK Resistance Mutations Identified from Liquid Biopsy in an ALK-Rearranged Squamous Cell Lung Cancer Patient Treated with Sequential ALK TKI Therapy: A Case Report
por: Yao, Bin, et al.
Publicado: (2021)

Quantitative immunohistochemistry (IHC) analysis of biomarker combinations for human esophageal squamous cell carcinoma
por: Gao, Jiebing, et al.
Publicado: (2021)

Detection of Circulating Tumor Cells by Fluorescent Immunohistochemistry in Patients with Esophageal Squamous Cell Carcinoma: Potential Clinical Applications
por: Li, Shu-Ping, et al.
Publicado: (2016)

Accurate and Economical Detection of ALK Positive Lung Adenocarcinoma with Semiquantitative Immunohistochemical Screening
por: Zhou, Jianya, et al.
Publicado: (2014)

Detection of ALK rearrangements in lung cancer patients using a homebrew PCR assay
por: Yu, Hui, et al.
Publicado: (2016)

The Molecular Detection and Clinical Significance of ALK Rearrangement in Selected Advanced Non-Small Cell Lung Cancer: ALK Expression Provides Insights into ALK Targeted Therapy
por: Zhang, Ning-Ning, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ob0ar8s1e0mrjtuqdstv0toari